TROP-2-Directed ADC Could Be New Standard for Some NSCLCs.
完整摘要 · 中文译文
在III期Opti-TROP-Lung06试验中,新诊断的PD-L1阴性、晚期非鳞状非小细胞肺癌且无可靶向变异的患者,接受靶向TROP-2的抗体偶联药物sacituzumab tirumotecan联合PD-1抑制剂帕博利珠单抗治疗,中位无进展生存期(PFS)为15个月。相比之下,接受标准化疗联合帕博利珠单抗治疗的患者中位PFS为5.7个月。
完整摘要 · 英文原文
In the phase III Opti-TROP-Lung06 trial, patients with newly diagnosed PD-L1-negative, advanced nonsquamous non-small cell lung cancer without targetable alterations who received the TROP-2-directed antibody-drug conjugate sacituzumab tirumotecan and the PD-1 inhibitor pembrolizumab experienced a median progression-free survival (PFS) of 15 months. In comparison, those patients who received standard chemotherapy plus pembrolizumab experienced a median PFS of 5.7 months.
摘要 待译
In the phase III Opti-TROP-Lung06 trial, patients with newly diagnosed PD-L1-negative, advanced nonsquamous non-small cell lung cancer without targetable alterations who received the TROP-2-directed antibody-drug conjugate sacituzumab tirumotecan and the PD-1 inhibitor pembrolizumab experienced a median progression-free survival (PFS) of 15 months. In comparison, those patients who received standard chemotherapy plus pembrolizumab experienced a median PFS of 5.7 months.